Wall Street brokerages expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings of ($1.44) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Aerie Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.50) and the highest estimate coming in at ($1.38). Aerie Pharmaceuticals posted earnings of ($0.72) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 100%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, March 6th.
On average, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($3.42) per share for the current financial year, with EPS estimates ranging from ($3.49) to ($3.34). For the next financial year, analysts forecast that the company will report earnings of ($2.29) per share, with EPS estimates ranging from ($2.38) to ($2.19). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Aerie Pharmaceuticals.
A number of research analysts have weighed in on AERI shares. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Zacks Investment Research lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Mizuho began coverage on Aerie Pharmaceuticals in a research note on Wednesday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a report on Sunday, September 17th. Finally, Cowen restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $71.43.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. grew its stake in shares of Aerie Pharmaceuticals by 11.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after acquiring an additional 275 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of Aerie Pharmaceuticals by 792.5% during the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after acquiring an additional 2,647 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Aerie Pharmaceuticals by 2,711.4% during the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after acquiring an additional 3,579 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Aerie Pharmaceuticals during the second quarter valued at about $204,000. Finally, Palisade Capital Management LLC NJ acquired a new stake in shares of Aerie Pharmaceuticals during the second quarter valued at about $212,000.
WARNING: “Zacks: Brokerages Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Post -$1.44 Earnings Per Share” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/03/zacks-brokerages-anticipate-aerie-pharmaceuticals-inc-aeri-to-post-1-44-earnings-per-share.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.